Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy

Open access
Narasimhan, Vignesh, Wright, Josephine A., Churchill, Michael, Wang, Tongtong, Rosati, Rachele, Lannagan, Tamsin R.M., Vrbanac, Laura, Richardson, Anne B., Kobayashi, Hiroki, Price, Timothy, Tye, Gayle X.Y., Marker, Julie, Hewett, Peter J., Flood, Michael P., Pereira, Shalini, Whitney, G. Adam, Michael, Michael, Tie, Jeanne, Mukherjee, Siddhartha, Grandori, Carla, Heriot, Alexander G., Worthley, Daniel L., Ramsay, Robert G., Woods, Susan L. · 2020 · Clinical Cancer Research

Abstract

Purpose: Patients with colorectal cancer with peritoneal metastases (CRPMs) have limited treatment options and the lowest colorectal cancer survival rates. We aimed to determine whether organoid testing could help guide precision treatment for patients with CRPMs, as the clinical utility of prospective, functional drug screening including nonstandard agents is unknown. Experimental Design: CRPM organoids (peritonoids) isolated from patients underwent parallel next-generation sequencing and medium-throughput drug panel testing ex vivo to identify specific drug sensitivities for each patient. We measured the utility of such a service including: success of peritonoid generation, time to cultivate peritonoids, reproducibility of the medium-throughput drug testing, and documented changes to clinical therapy as a result of the testing. Results: Peritonoids were successfully generated and validated from 68% (19/28) of patients undergoing standard care. Genomic and drug profiling was completed within 8 weeks and a formal report ranking drug sensitivities was provided to the medical oncology team upon failure of standard care treatment. This resulted in a treatment change for two patients, one of whom had a partial response despite previously progressing on multiple rounds of standard care chemotherapy. The barrier to implementing this technology in Australia is the need for drug access and funding for off-label indications. Conclusions: Our approach is feasible, reproducible, and can guide novel therapeutic choices in this poor prognosis cohort, where new treatment options are urgently needed. This platform is relevant to many solid organ malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-0073

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 185

Metadata

Authors
Narasimhan, V., Wright, J. A., Churchill, M., Wang, T., Rosati, R., Lannagan, T. R. M., Vrbanac, L., Richardson, A. B., Kobayashi, H., Price, T., Tye, G. X. Y., Marker, J., Hewett, P. J., Flood, M. P., Pereira, S., Whitney, G. A., Michael, M., Tie, J., Mukherjee, S., Grandori, C., Heriot, A. G., Worthley, D. L., Ramsay, R. G., & Woods, S. L.
Venue
Clinical Cancer Research
Published
2020-07-15
Volume
26
Issue
14
Pages
3662-3670
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3021386253
Cited by
185
References
15
FWCI
8.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-0073
The paper
Narasimhan, V., Wright, J. A., Churchill, M., Wang, T., Rosati, R., Lannagan, T. R. M., Vrbanac, L., Richardson, A. B., Kobayashi, H., Price, T., Tye, G. X. Y., Marker, J., Hewett, P. J., Flood, M. P., Pereira, S., Whitney, G. A., Michael, M., Tie, J., Mukherjee, S., . . . Woods, S. L. (2020). Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-0073

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.